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Abstract 25 
G protein-coupled receptors (GPCRs), the largest family of integral membrane proteins, 26 
participate in the regulation of many physiological functions and are the targets of around 27 
30% of currently marketed drugs. However, knowledge of the structural and molecular bases 28 
of GPCR function remains limited, owing to difficulties related to their overexpression, 29 
purification and stabilization. The development of new strategies aimed at obtaining large 30 
amounts of functional GPCRs is therefore crucial. Here, we review the most recent advances 31 
in production and functional folding of GPCRs from Escherichia coli inclusion bodies. Major 32 
breakthroughs open exciting perspectives for structural and dynamic investigations of 33 
GPCRs. In particular, combining targeting to bacterial inclusion bodies with amphipol-34 
assisted folding is emerging as a highly powerful strategy.  35 
36 
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Overexpressing membrane proteins for structural and biophysical studies: still a 37 
challenge 38 
Structural information on integral membrane proteins (IMPs) remains limited. 39 
According to databases of known three-dimensional (3D) structures of IMPs 40 
(http://blanco.biomol.uci.edu/Membrane_proteins_xtal.html; http://www.mpdb.tcd.ie; 41 
http://www.drorlist.com/nmr/MPNMR.html), the crystal or NMR structures of only ~280 42 
IMPs have been solved to date, as compared to tens of thousands of soluble proteins. Worse, 43 
only a small fraction (~35%) of these proteins are eukaryotic, even though IMPs constitute 44 
20-30% of the proteins encoded by human and other eukaryotic genomes. Among IMPs, G 45 
protein-coupled receptors (GPCRs), whose transmembrane region is a 7-helix bundle, 46 
constitute the largest family [1]. More than 800 GPCRs have been identified, representing 2-47 
3% of the coding sequences in the human genome. They are involved in most essential 48 
cellular processes and are the targets of around 30% of current pharmaceutical drugs. It is 49 
therefore critical to gain detailed knowledge of their structures and their dynamics in order to 50 
understand their functions and/or dysfunctions, as well as to rationally design selective 51 
therapeutic compounds. However, except for rhodopsin, whose crystal structure has been 52 
solved following its extraction from the retina [2,3], the low natural abundance of GPCRs 53 
generally precludes their purification in biochemically relevant amounts. Overexpression is 54 
thus a prerequisite to investigating their structure or analyzing their conformational transitions 55 
upon interaction with ligands or with signaling proteins like G proteins and arrestins.  56 
Overexpressing GPCRs, however, is still problematic, often resulting in low yield, 57 
protein aggregation or misfolding, if not cell toxicity. Consequently, although crystal 58 
structures of ligand-bound β1- and β2-adrenergic [4,5], adenosine A2A [6], chemokine CXCR4 59 
[7], and dopamine D3  [8] receptors have been recently reported, investigating the structure 60 
and dynamics of most GPCRs remains a daunting task. Many overexpression systems have 61 
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been tested. GPCRs have been successfully produced by cell-free synthesis [9] and by 62 
heterologous expression in mammalian [10] and insect [11] cells, in the photoreceptor cells of 63 
Drosophila [12], Xenopus [13] and mouse [14], and in such microbes as yeasts and bacteria 64 
[15,16]. As discussed below, expression in Escherichia coli holds great promises, not only 65 
due to its simplicity, rapidity, safety, scalability or genetic tractability, but also in terms of 66 
quantity and homogeneity of the recombinant protein.  67 
Once efficient expression has been achieved, purifying sufficient amounts of native-68 
like, functional and stable protein still remains a formidable challenge. GPCRs, as all IMPs, 69 
have to be handled in aqueous solutions in complex with surfactants, usually detergents. 70 
Because detergents tend to be inactivating, identifying a detergent or lipid/detergent mixture 71 
that ensures protein homogeneity, functionality and stability is often a limiting step. 72 
Nevertheless, several overexpressed GPCRs have been successfully purified in a stable (often 73 
engineered) and functional form, allowing their crystallization and structure determination. 74 
For instance, the adenosine A2A receptor has been purified in a fully functional form and 75 
crystallized in n-dodecyl-β-D-maltopyranoside (DDM) mixed with cholesterol hemisuccinate 76 
(CHS) [6]. The β1-adrenergic receptor has been crystallized in octylthioglucoside [4], whereas 77 
the β2-adrenergic receptor was best solubilized, purified and crystallized in DDM [5]. DDM 78 
was also compatible with NMR spectroscopy analysis of the β2-adrenergic receptor [17]. 79 
While DDM is often used, it seems that an optimized surfactant environment has to be 80 
identified for each GPCR. Amphipols (APols), a new class of surfactants, can efficiently 81 
substitute for detergents to stabilize IMPs and offer a very promising alternative medium [18]. 82 
This review focuses on GPCR bacterial expression and on their functional folding using 83 
APols. 84 
 85 
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Overexpression of GPCRs in bacteria: targeting the inner membrane or inclusion 86 
bodies? 87 
GPCRs have been overexpressed in bacteria following two different approaches. Since 88 
GPCRs are plasma membrane proteins, targeting recombinant receptors to the inner 89 
membrane of the bacterium was initially considered as the most obvious strategy (Figure 1). 90 
In most cases, however, this leads to severe cell toxicity and low levels of expression. A more 91 
efficient insertion into the bacterial inner membrane can be achieved by fusing the GPCR to a 92 
protein helper partner. Thus, coupling E. coli β-galactosidase (114 kDa) to the N-terminus of 93 
the human β2-adrenergic receptor led to measurable membrane expression [19]. The 94 
combination of E. coli maltose-binding protein (MBP, 43 kDa), used as an N-terminal fusion 95 
partner, with E. coli thioredoxine A (TRX, 10 kDa), added at the C-terminus of the GPCR, 96 
has been shown to be particularly well adapted for expression of the rat neurotensin NTS1 or 97 
the cannabinoid CB2 receptors [20]. The human adenosine A2A receptor has been highly 98 
expressed with only MBP fused at the N-terminus [21]. Fusion of the jellyfish green 99 
fluorescent protein (GFP, 27 kDa) to the C-terminus of the human cannabinoid CB1 and 100 
bradykinin B2 receptors has led to efficient membrane expression [22]. Although membrane 101 
expression of the neurotensin receptor has been demonstrated to be highly successful and 102 
applied to automated large-scale purification [23], the MBP-GPCR-TRX fusion strategy 103 
cannot be generally applied without extensive receptor truncations or modifications. 104 
Expression of heterologous proteins in E. coli is frequently associated with incorrect 105 
folding and accumulation of the recombinant protein in cytoplasmic aggregates named 106 
inclusion bodies (IBs). Targeting GPCRs to IBs combines many advantages. IBs are mechani-107 
cally stable and can be easily isolated from other cell constituents by centrifugation, they are 108 
not toxic to the cell, and they are resistant to proteolytic degradation. Production of GPCRs in 109 
IBs can be massive (Table 1). It implies, however, that the receptors thus expressed have to 110 
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be subsequently refolded to their native state, which constitutes a difficult challenge (see 111 
below).  This strategy has been first successfully developed for the rat olfactory OR5 receptor 112 
and several other GPCRs [24], and subsequently improved for the human leukotriene BLT1 113 
and the human serotonin 5-HT4A receptors [25,26]. In most cases, once again, a fusion partner 114 
is needed for efficient production (Figure 1). Except for the BLT1 receptor, which has been 115 
expressed in IBs after fusion to a short T7 tag [25], most GPCRs were coupled to a large 116 
fusion partner such as the schistosomal glutathione S-transferase (GST, 25 kDa), and had to 117 
be truncated at their N-termini. The serotonin 5HT4A receptor was efficiently expressed after 118 
fusion to bacterial ketosteroid isomerase (KSI, 12 kDa) [26], but KSI proved to be inefficient 119 
for other receptors (J.-L. Banères, unpublished). A recent high-throughput effort at large-scale 120 
production of more than 100 GPCRs as bacterial IBs has shown that a majority of them can 121 
be expressed in quantities sufficient for solubilization and purification [27,28]. This extensive 122 
study evaluated the efficiency of various fusion partners, namely GST, MBP, TRX or the E. 123 
coli N-utilization substance A (NusA, 50 kDa), to target GPCRs to IBs. Depending on culture 124 
conditions, GST and TRX were identified as most efficient, although some GPCRs could be 125 
overexpressed without any protein tag.  126 
The use as targeting partner of an α5 integrin fragment (α5I, 31 kDa) has allowed 127 
many rhodopsin-like GPCRs to be expressed at high levels regardless of their length (from 128 
337 to 472 amino acids), their G protein coupling selectivity, or the nature of their 129 
endogenous ligands. This efficient and apparently generic procedure has been successfully 130 
applied to expressing the β3-adrenergic receptor, the vasopressin V2 and V1b and oxytocin 131 
OTR receptors, the chemokine CCR5 and CXCR4 and chemokine-like ChemR23 receptors, 132 
the ghrelin GHS-1a receptor, the cannabinoid CB1 receptor and the leukotriene BLT1, BLT2, 133 
CysLT1 and CysLT2 receptors, without requiring any optimization of either the GPCR 134 
coding sequence, the cell culture conditions, or the extraction/purification procedures [29,30]. 135 
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The α5I fusion strategy represents an important breakthrough for in vitro studies aimed at 136 
understanding the molecular bases of GPCR function and structure, and potentially for other 137 
membrane protein families. 138 
Comparison of the different expression strategies in E. coli (Table 1) suggests that 139 
targeting GPCRs to IBs, presents an interesting potential in terms of both the amounts 140 
produced and general applicability. 141 
 142 
Functional folding of GPCRs from IBs using classical surfactants: the state of the art 143 
Following expression, IBs are first solubilized under denaturing conditions. Then, 144 
following purification (using a metal-affinity chromatography procedure for instance), the 145 
fusion partner used for high-level expression has to be removed, usually through proteolytic 146 
cleavage. A notable advantage of α5I-GPCR fusions regarding this crucial biochemical step is 147 
that α5I keeps the receptor soluble after dialysis in the absence of denaturing agents, greatly 148 
facilitating an efficient proteolytic cleavage of the fusion protein [29]. After another 149 
purification step in SDS buffers, folding is then initiated by transfer from SDS to other 150 
surfactants (Figure 2). Folding efficiency depends on the competition between protein 151 
aggregation and 3D structure formation as well as on the ability of the receiving surfactant to 152 
stabilize the native 3D state of the folded receptor [31].  153 
Efficient folding implies that the solubilized protein is not aggregated to start with. 154 
Globular proteins expressed in IBs can be efficiently solubilized by chaotropic agents such as 155 
urea or guanidinium chloride. In contrast, the solubilization of IMPs requires harsh detergents 156 
such as sodium dodecyl sulfate (SDS) or N-lauroylsarcosine (or organic solvents). In SDS, 157 
proteins in general and, in particular, IMPs such as bacteriorhodopsin (BR) [32], the µ-opioid 158 
receptor [33] or the small multidrug transporter EmrE [34], retain or acquire a significant 159 
amount of α-helical secondary structure. Given that some of the helical segments present in 160 
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SDS solution are likely to overlap regions that form transmembrane helices in the folded 161 
protein, a SDS-solubilized GPCR should probably be considered not as fully unfolded, but 162 
rather as partially prefolded, as far as the secondary structure is considered. If we look at the 163 
µ-opioid receptor as a GPCR reference, its α-helical content determined in 0.1% SDS 164 
solution is around 40% at pH 7-8 [33], a value in agreement with the predicted secondary 165 
structure of the full-length protein (50-54%). 166 
GPCR folding is initiated by displacing the denaturing detergent with a milder surfact-167 
ant. Under these conditions, regions that have a propensity to fold may do so, allowing native-168 
like interactions between folded segments to form. These can be intramolecular, which may 169 
lead to correct folding, or intermolecular, leading to aggregation. Finding favorable folding 170 
conditions therefore implies identifying a surfactant or surfactant mixture that will favor 171 
intramolecular interactions and then efficiently stabilize the native fold of the protein. Various 172 
such environments have been reported so far, although the limited number of successful 173 
examples makes inferring general rules difficult. The refolding environments include classical 174 
detergents and lipid/detergent mixtures, bicelles, lipid vesicles and, finally, original 175 
surfactants such as APols (Figure 2). 176 
Efficient folding in detergents has been reported for a limited number of GPCRs such 177 
as the leukotriene receptors BLT1 and BLT2 (Table 2). BLT1 was folded as a functional 178 
protein to ~30% in LDAO [25] whereas the BLT2 receptor was folded as a functional state to 179 
~4% in DPC/HDM mixtures [29]. In both cases, adding lipids (e.g. asolectin) was required for 180 
improving the percentage of functional recovery. Other GPCRs have been reported to 181 
efficiently fold in detergent micelles. As stated above, the OR5 receptor was first folded in 182 
digitonin before insertion in lipid vesicles [24]. Fluorescence-monitored ligand binding assays 183 
demonstrated that about 80% of the folded OR5 receptor bound its lilial ligand [24]. More 184 
recently, refolding of the SDS-solubilized parathyroid hormone receptor 1 (PTH-1R) and of 185 
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CB1 receptors has been performed by exchanging the SDS for a mixture of the non-ionic 186 
detergents DDM and Cymal 6 [28]. In this study, ligand binding assays demonstrated that 187 
~30% of the folded CB1 was functional. The glucagon-like peptide-1 receptor (GLP-1R) has 188 
been reported to fold upon transfer from SDS to Brij78 as a functional protein to ~40% [35]. 189 
In all these cases, i.e. for the PTH1R, CB1 and GLP-1R, the folding process was carried out 190 
in the presence of methyl-β-cyclodextrin, used to strip off SDS. Removal of dodecylsulfate 191 
can also be achieved by precipitation using K+ ions (see below) [36].  192 
The efficiency of alternate membrane-like environments to fold and stabilize GPCRs 193 
recovered from IBs has also been explored. Certain mixtures of long-chain and short-chain 194 
phospholipids assemble as bilayer discs, called bicelles, which mimic the membrane 195 
environment (Figure 2). A limited number of GPCRs, specifically the serotonin 5-HT4A [26] 196 
and the neuropeptide Y2 receptors [37], have been folded to a native-like conformation in 197 
DMPC/CHAPS bicelles with folding yields of ~25 % and ~65%, respectively. 198 
A few cases of successful folding in lipid vesicles of GPCRs recovered from IBs have 199 
also been reported. The first such example was described in the pioneering work of Kiefer’s 200 
group on the OR5 olfactory receptor, in which the overexpressed receptor was solubilized in 201 
the strong, negatively charged detergent N-lauroylsarcosine and then folded by transfer to the 202 
non-denaturing detergent digitonin [24]. The digitonin-folded receptor was able to bind its 203 
ligand (see above), thus providing yet another example of successful folding in detergent. The 204 
OR5 receptor was subsequently reconstituted in lipid vesicles by supplementing it with 205 
DDM/POPC/POPG mixtures before removing the detergent by adsorption onto hydrophobic 206 
beads. Under such conditions, the protein was stabilized in a fully ligand-competent state 207 
(~1% of the solubilized and purified material), as assessed by photoaffinity labeling.  208 
As in the case of bicelles, successful folding of GPCRs by direct transfer to lipids is 209 
limited to a few examples, such as the human neuropeptide Y1 receptor [38].  210 
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 211 
Amphipol-assisted folding of GPCRs: a generic approach? 212 
As summarized in the previous section, folding in detergents or detergent/lipid mixtu-213 
res has thus far yielded only a handful of functional GPCRs. Moreover, even for those GPCRs 214 
that have been folded under such conditions, folding yields are usually low, conditions are 215 
highly idiosyncratic, and identifying them is very time-consuming. Developing a more 216 
general approach to folding GPCRs recovered from IBs would be of great interest. This has 217 
led to testing APols as a possible generic folding medium. 218 
APols were initially designed, synthesized and validated as mild alternatives to classi-219 
cal detergents [39]. They are defined as “amphipathic polymers that are able to keep indivi-220 
dual IMPs soluble under the form of small complexes” [18]. What is of interest here is that : 221 
(i) most IMPs are more (and generally much more) stable in APols than they are in detergent 222 
solutions [18,40], and (ii) APols have proven an efficient medium in which to fold IMPs to 223 
their native state [41,42]. APols are relatively short polymers (their mass is typically in the 8-224 
20-kDa range) that carry a high density both of hydrophobic chains and of highly hydrophilic 225 
groups. The prototypal APol, named A8-35 (Figure 3A) [40,41], remains by far the most 226 
thoroughly studied and most widely used APol [18,43,44]. The high solubility of A8-35 in 227 
water is due to the presence of carboxylates. As a consequence, A8-35 becomes insoluble in 228 
acidic solutions [45,46], a limitation that has prompted the development of alternative 229 
chemical structures such as sulfonated APols (SAPols; Figure 3B) [47] or glucose-based, 230 
non-ionic APols (NAPols; Figure 3C) [48,49], both of which are insensitive to pH. In aque-231 
ous solutions, APols form small, micelle-like particles, each of which comprises only a few 232 
APol molecules (~4 of them in the case of A8-35) [46]. 233 
IMP/APol complexes are typically obtained by one of the two following routes. 234 
Usually, a native IMP in detergent solution is supplemented with APols. This results in the 235 
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formation of ternary complexes [50,51]. The detergent is then removed, yielding small, 236 
compact IMP/APol complexes [52], in which the APol forms a thin layer covering the 237 
hydrophobic transmembrane surface of the protein [53,54]). Alternatively, a denatured IMP in 238 
SDS and/or urea is transferred to APols, during which process it recovers or adopts its native 239 
3D structure (Figure 2, and see below). As a rule, APol-trapped IMPs are much more stable 240 
than their detergent-solubilized counterparts [18,40]. The underlying mechanisms are several. 241 
The most important factor is that APols are less efficient than detergents at disrupting the pro-242 
tein/protein and protein/lipid interactions that determine and stabilize the 3D structure of 243 
IMPs [40,47]. This led to the suggestion that, in addition to being less aggressive towards 244 
properly folded, native IMPs, APols might provide a favorable medium for the formation or 245 
reformation of native-like interactions starting from a denatured protein. 246 
APol-mediated IMP folding was first demonstrated using as models urea-solubilized 247 
OmpA and FomA, two β-barrel outer membrane proteins (OMPs) from the eubacteria E. coli 248 
and Fusobacterium nucleatum, respectively, and a paradigmatic α-helical IMP, BR, a light-249 
driven proton pump from the plasma membrane of the archaebacterium Halobacterium 250 
salinarium [41]. In the latter case, the SDS-solubilized BR was folded by precipitating 251 
dodecylsulfate as its potassium salt [36] in the presence of A8-35. The rationale behind the 252 
choice of this apparently particular procedure is to proceed as rapidly as possible to the 253 
exchange of SDS for APols, leaving protein little chance to explore misfolding or aggregation 254 
opportunities offered by partially denaturing environments. Precipitation achieves this goal 255 
much more efficiently than dialysis, adsorption of the detergent onto BioBeads or cyclo-256 
dextrins, or exchange of surfactants after immobilization of the protein onto an affinity chro-257 
matography column. 258 
It is truly remarkable that APols favored the folding of two families of IMPs with 259 
completely different structures as OMPs and BR, suggesting that the approach could be quite 260 
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general. This led to testing it on GPCRs recovered under denaturing conditions (namely in the 261 
presence of SDS) from E. coli IBs [42]. Conditions initially established to refold BR were 262 
applied essentially without any changes to folding six GPCRs, namely the leukotriene B4 263 
receptors BLT1 and BLT2, the serotonin receptor 5-HT4A, the cannabinoid CB1 receptor [42] 264 
and, more recently, the ghrelin GHSR-1a and the vasopressin V2 receptors (J.-L. Banères and 265 
B. Mouillac, unpublished). Folding yields between 30 and 50% were systematically achieved, 266 
depending on the receptor considered (these determinations were based on ligand binding 267 
studies). They rose up to 60-70% in the presence of lipids (Table 2). It has been observed that 268 
the presence of lipids increases the stability of APol-trapped GPCRs [42]. One possibility is 269 
that they do so by binding to sites that form when the transmembrane surface achieves its 270 
native state. Thereby, they would contribute to driving folding towards the latter. As observed 271 
for most APol-trapped MPs, GPCRs folded in A8-35 are significantly more stable than those 272 
kept in lipid/detergent mixtures [42], which is of great interest for subsequent investigations 273 
[55]. The BLT1 and GHSR-1a receptors have also been folded in NAPols, with yields similar 274 
to those achieved in A8-35 (J.-L. Banères, unpublished). Although less thoroughly studied 275 
than A8-35, NAPols can be of interest when the purified proteins under study must be 276 
handled or studied at acidic pH, when their ligands tend to interact with polyanions such as 277 
A8-35, as is the case with ghrelin and vasopressin, or when studying the kinetics of 278 
interaction of G proteins with activated GPCRs, which is slowed down in the presence of 279 
A8-35 (J.-L. Banères, unpublished).  280 
From a fundamental point of view, we note that seven α-helical IMPs (BR and six 281 
GPCRs) have now been successfully refolded into a synthetic polymer, APol A8-35, whose 282 
chemical structure and supramolecular organization bear no similarity, beyond the 283 
amphiphilic character, to lipid bilayers. This indicates that, at least for these proteins, neither 284 
an environment mimicking the highly complex and anisotropic lipid bilayer nor even the 285 
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presence of lipids is required for transmembrane helices to form and correctly orient and pack 286 
with each other, and for the polypeptide to adopt its functional 3D structure. This is consistent 287 
with the general notion that all of the chemical information needed for proteins, including 288 
IMPs, to correctly fold is stored in their sequences. 289 
From a more practical perspective, conditions initially established to refold BR have 290 
been applied without much change to refolding of six distinct GPCRs, with functional yields 291 
between 30 and 70%. Should this approach turn out to be sufficiently general and easy to 292 
implement, as these data suggest, it would represent an important breakthrough for in vitro 293 
studies aimed at understanding the molecular bases of the function of rhodopsin-like GPCRs 294 
and, possibly, of many other IMPs. It is to be noted in this context that all of those IMPs that 295 
have been refolded to date using APols, although they display different length (for instance 296 
262 amino acids for BR versus 472 amino acids for CB1), have relatively simple structures. 297 
In particular, none of them displays extended, complex extramembrane domains like GPCRs 298 
from classes B (secretin receptor-like) and C (glutamate receptor-like) or from adhesion and 299 
frizzled families. It is currently an open question whether APols would favor or interfere with 300 
the folding of such large N-terminal extracellular structures. It would be of interest to express 301 
and fold some reference GPCRs from classes B or C following the α5I-amphipol expression-302 
folding strategy described above to assess whether the presence of their large soluble N-303 
termini may influence expression and functional folding. As indicated before, the class B 304 
GPCR GLP-1R has been accumulated in bacterial IBs and functionally folded by transfer 305 
from SDS to Brij78 in the presence of methyl-β-cyclodextrin [35]. However the N-terminal 306 
domain of GLP-1R is rather short (predicted to be 122 amino acids). In addition, trials to 307 
overexpress metabotropic glutamate receptors from the GPCR class C in E. coli IBs were not 308 
successful [27], but the α5I fusion strategy has not been applied to these targets so far. 309 
Scrambling of disulfide bridges has not been a problem until now, but will undoubtedly be in 310 
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some cases. It may possibly be alleviated by careful control of the redox potential during and 311 
after folding, and/or by genetic engineering. 312 
 313 
What to do next? 314 
Once a GPCR has been folded using APols, it can be studied in this environment, or 315 
transferred to another one. Most biochemical and biophysical techniques can be applied to 316 
APol-trapped MPs (Table 3) [18]. There are reasons to believe that studying protein-protein 317 
interactions like oligomerization of GPCRs or recruitment of non-membrane protein partners 318 
from signaling complexes can be performed in APols. First, the binding of large soluble 319 
toxins and of antibodies to APol-trapped IMPs has already been described [40,56], and these 320 
data are promising considering GPCRs and their signaling proteins. Second, GPCRs 321 
expressed in IBs and subsequently folded in detergent:lipid mixed micelles can be isolated as 322 
dimers that can be used for characterizing molecular events that occur upon activation [29, 323 
57,58]. In the same way, trapping with APols does not prevent GPCRs from assembling into 324 
dimers [42].  Purified GPCRs can also interact functionally with signaling proteins. This is 325 
true for G proteins with receptors folded in mixed micelles [29,57,58] but also applies to 326 
receptors folded in APols. Indeed, both G proteins (Gs/Gq)  and arrestins can bind to APols-327 
trapped vasopressin V2 and ghrelin GHSR-1a GPCRs, respectively (J.-L. Banères and B. 328 
Mouillac, unpublished). Cryo-electron microscopy can be applied to APol-trapped IMP 329 
complexes [59] and supercomplexes (T. Althoff, PhD thesis, University of Frankfurt-am-330 
Main, 2011), whose structure can then be solved by single-particle image analysis. This 331 
approach could conceivably be applied to studying the arrangement of GPCRs associated into 332 
dimers (oligomers) and/or interacting with their associated signaling proteins. Since 333 
complexation by APols is compatible with ligand binding studies [18,42,55,56,60], trapping 334 
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with an appropriately functionalized APol would provide a straightforward and very general 335 
approach to immobilizing GPCRs onto solid supports for ligand screening [56].  336 
There are cases where one will wish to transfer the folded GPCR to another environ-337 
ment. Direct transfer of IMPs from APols to lipid vesicles or black films has been demonstra-338 
ted [41,61]. The procedure, however, is unlikely to be applicable to GPCRs, which are fragile 339 
proteins and will stand great risks of being denatured in the process. A likely safer route 340 
would be to exchange the APol for detergent or lipid/detergent mixed micelles, which is 341 
readily possible [50,51,62], and then to proceed to a classical reconstitution.  342 
Crystallization of APol-trapped IMPs is still in its infancy [18]. Crystallization of a 343 
GPCR that has been folded using APols should probably best be attempted after transferring 344 
the receptor either to a detergent solution, to bicelles, to a lipidic cubic phase or sponge phase. 345 
NMR, on the other hand, appears as a particularly promising route to studying the structure of 346 
ligands bound to APol-trapped GPCRs, ligand-induced conformational transitions and, 347 
possibly, at least some aspects of GPCR structure. Several small IMPs in complexes with 348 
APols have been studied to date by solution NMR (T. Dahmane, PhD thesis, University of 349 
Paris 7, 2007; P. Bazzacco, PhD thesis, Université of Paris 7, 2009) [53,54,63,64]. 350 
GPCR/APol complexes, because of their large size, remain difficult to study in toto. 351 
However, transferred nuclear Overhauser effects (trNOEs) can be exploited to determine the 352 
structure of GPCR-bound ligands. In a recent study, deuterated BLT2 receptor was folded and 353 
stabilized using a partially deuterated version of the amphipol A8-35. One of its ligands, the 354 
leukotriene LTB4, was then added in its hydrogenated form, and its receptor-bound structure 355 
determined from the magnitude of 89 trNOE signals [55]. The range of NMR studies 356 
applicable to APol-trapped GPCRs ought to be extended by developments in the chemistry of 357 
APols, such as the availability of a perdeuterated version of A8-35 (F. Giusti, unpublished) or  358 
of pH-insensitive APols such as  SAPols (Figure 3B; T. Dahmane, PhD thesis, Université 359 
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Paris 7, 2007) [47] and non-ionic NAPols (Figure 3C; P. Bazzacco, PhD thesis, Université 360 
Paris 7, 2009) [48,49]. 361 
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Table 1. Level of production of several purified GPCRs following expression in E. coli  526 
 527 
 528 
GPCRa  Fusion partner(s)      Site of   Yield (mg/L)b  Refs. 529 
                 expression   530 
___________________________________________________________________________531 
Neurotensin  MBP + TRX  Inner membrane 0.13c     [20] 532 
NTS1                     533 
 534 
Adenosine  MBP   Inner membrane 0.17     [21] 535 
A2a          536 
 537 
Olfactory  GST   IBs   0.2     [24]  538 
OR5          539 
 540 
Leukotriene  T7 tag   IBs   2-3     [25] 541 
BLT1          542 
 543 
Serotonin  KSI   IBs   0.5     [26] 544 
5HT4A          545 
 546 
Cannabinoid  none   IBs   100c     [28] 547 
CB1           548 
 549 
Vasopressin V2, α5I   IBs   0.8-1.2     [29] 550 
leukotriene BLT2        551 
   552 
aFor each GPCR, the fusion partner(s) and the site of expression in the bacterium, namely the 553 
inner membrane or inclusion bodies (IBs), are indicated.  554 
bIn each case, the quantity of pure and functional GPCR that has been obtained is indicated in 555 
mg/L of cell suspension. A functional receptor means that it has been overexpressed, separat-556 
ed form its fusion partner (if applicable) by enzyme cleavage, folded and/or purified and its 557 
activity checked by ligand binding. 558 
cExcept for CB1 and NTS1, which were produced in fermentors, all other receptors have been 559 
overexpressed in culture flasks. 560 
561 
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Table 2. Comparison of GPCR folding yields obtained in different surfactants 562 
 563 
GPCR   Folding medium   Average maximum  Refs.564 
         folding yield (%)a 565 
BLT1   Detergent/lipid mixed micelles 30     [25] 566 
   (LDAO/asolectin) 567 
 568 
   A8-35     50     [42] 569 
  570 
   A8-35/asolectin   65    [42] 571 
 572 
 573 
 574 
BLT2   Detergent/lipid mixed micelles 4     [29] 575 
   (DPC/HDM/asolectin) 576 
 577 
   A8-35     50     [42] 578 
 579 
A8-35/asolectin   70     [42] 580 
 581 
 582 
5-HT4A  DMPC/CHAPS bicelles  25     [26] 583 
 584 
   A8-35     30     [42] 585 
 586 
A8-35/asolectin   60     [42] 587 
 588 
 589 
CB1    Detergent/lipid mixed micellesb 0    [42] 590 
   (Fos-choline-16/asolectin) 591 
 592 
   A8-35     30    [42] 593 
 594 
   A8-35/asolectin   40     [42] 595 
 596 
   Detergent mixed micelles  30    [28] 597 
   (DDM/Cymal 6) 598 
    599 
 600 
aThe folding yield is the amount of functional protein obtained after folding (based on binding 601 
of specific ligands) compared to that of protein in starting SDS solution (based on A280 602 
measurements).   603 
bNo extensive detergent screening was carried out to optimize folding of the CB1 receptor in 604 
detergent/lipid mixed micelles. 605 
606 
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Table 3. Applicability of various approaches to handling and studying GPCR/APol 607 
complexes 608 
 609 
Approach Applicability Remarks Refs. 
UV-visible absorp-
tion and fluores-
cence spectro-
scopy, CD 
Yes, but for infra-red studies 
in the amide absorption bands. 
All APols validated to date contain amide 
bonds. 
[41,50,52] 
Ligand-binding and 
functional studies 
Yes. Damping of large-scale transmembrane 
conformational changes may occur. 
NAPols to be favored for G protein and 
arrestin binding studies, as well as for 
binding studies with cationic amphipathic 
ligands. 
[42,47,52,55,
56,60,65] 
Purification Most purification techniques: 
ultracentrifugation, size exclu-
sion chromatography, immo-
bilized metal and ligand-based 
affinity chromatography… 
With charged APols, ionic exchange chro-
matography and isoelectric focusing to be 
avoided. 
[42,50,52] 
Electron microsco-
py, atomic force 
microscopy 
Single particles studied by EM 
after negative staining and by 
cryoEM. 
No AFM studies reported yet. [18,52,59,66] 
Immobilization 
onto solid supports 
Yes. Immobilization can be either direct or 
mediated by an appropriately functionaliz-
ed APol. 
[40,56] 
NMR Yes. Tested with A8-35, SAPols and NAPols, 
the latter two giving access to lower pH. 
Only A8-35 has been deuteriated yet. No 
solid-state studies reported yet. 
[53-55,63] 
Mass spectrometry Yes. Study in progress. [54] 
X-ray 
crystallography 
Remains to be developed. Transfer to detergent or lipid cubic phase. [18] 
 610 
611 
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Figure legends 612 
Figure 1. Strategies to overexpress GPCRs in E. coli. GPCRs can be produced in bacteria 613 
either by insertion into the inner membrane  or by accumulation into inclusion bodies . In 614 
the first case, a protein partner is coupled at the N-terminus (MBP, β-gal) or C-terminus 615 
(GFP, TRX) of the receptor, or at both extremities (for instance MBP and TRX), so as to 616 
target the recombinant protein to the membrane. In the second case, targeting to IBs is 617 
favored by coupling to the N-terminus another fusion partner, such as GST, KSI, TRX, NusA 618 
or α5I. GPCRs accumulated as inclusion bodies are not adequately folded and have to be 619 
solubilized in a harsh detergent before folding. 620 
 621 
Figure 2. Strategies to fold GPCRs from IBs. Before folding, the recombinant GPCR 622 
accumulated in IBs has to be solubilized in denaturing buffers (for instance a mix of urea and 623 
SDS), purified by immobilized-metal affinity chromatography (IMAC) and dialyzed in an 624 
aqueous buffer to eliminate most SDS and allow removal of the fusion partner, for instance 625 
via a thrombin cleavage. After elimination of the cleaved fusion partner through a second 626 
IMAC purification in denaturing conditions, the GPCR is kept soluble in SDS solution in 627 
which it displays a significant content of helicity. Folding can be achieved by transfer from 628 
SDS to mild detergents or amphipols, supplemented or not with lipids. The functional fraction 629 
of the GPCR preparation can be evaluated using pharmacological assays (ligand binding, 630 
activation of purified G proteins or arrestins). 631 
 632 
Figure 3. Chemical structures of three families of APols. A) A8-35, the prototypal APol. 633 
B) Sulfonated APol (SAPol). C) Glucose-based non-ionic APol (NAPol). 634 
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